| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.18 | 0.1 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.087 | 0.1 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.1 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.085 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.084 | 0.1 |